Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 29, 2025 09:15 ET | Source: Autonomix Medical, Inc.

Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System

GLP study marks a key milestone in Autonomix's path to achieve regulatory approvals Company remains on track to submit Investigational Device Exemption (“IDE”), and if approved, commence U.S....
August 20, 2025 08:30 ET | Source: Autonomix Medical, Inc.

Autonomix Medical, Inc. Granted New European Patent for First-in-Class Catheter-Based Technology

Global patent estate encompasses 80 issued patents and 40 pending patent applications Strengthens strategic position in a multi-billion-dollar market opportunity across cardiovascular, renal, and...
August 18, 2025 09:15 ET | Source: Autonomix Medical, Inc.

Autonomix Medical, Inc. to Participate in Virtual Investor Webinar Hosted by Ladenburg Thalmann & Co. Inc.

Live video webcast on Thursday, August 21st at 1:00 PM ET Register here THE WOODLANDS, TX, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”),...
August 14, 2025 08:30 ET | Source: Autonomix Medical, Inc.

Autonomix Medical, Inc. Finalizes Design Review of First-Ever Intravascular Nerve Sensing Catheter in Key Step Toward U.S. Clinical Studies

Microchip-based platform enables real-time nerve mapping and targeted treatment from within the vascular system Continued progress toward submitting Investigational Device Exemption (“IDE”), and if...
July 07, 2025 08:30 ET | Source: Autonomix Medical, Inc.

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment

THE WOODLANDS, TX, July 07, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted...
June 30, 2025 08:30 ET | Source: Autonomix Medical, Inc.

Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study

Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain PoC 2 phase builds on early success and positive results demonstrated in PoC 1 in...
May 13, 2025 09:20 ET | Source: Autonomix Medical, Inc.

Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market

Discussion in Virtual Investor CEO Connect focuses on Company’s planned follow-on market expansion study phase (“PoC 2”) of proof-of-concept trial; Access Here Additional indications potentially...
April 16, 2025 08:30 ET | Source: Autonomix Medical, Inc.

Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology

New patent underscores breadth of application and expansion opportunities for Company’s catheter-based technology Continued progress with growing global patent portfolio to over 80 issued patents...
February 26, 2025 09:00 ET | Source: Autonomix Medical, Inc.

Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the LSI USA ’25 Emerging Medtech Summit

THE WOODLANDS, TX, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to...
February 19, 2025 09:00 ET | Source: Autonomix Medical, Inc.

Autonomix Medical, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here THE WOODLANDS, TX, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company...